“
“In the title compound, (C6H16N)[Zn(C6H4N3)(3)](n), the Zn-II atom has a distorted tetrahedral geometry defined by four N atoms from four benzotriazolate (BTA) ligands.

The compound is composed of extended polymeric chains in which two BTA N atoms bridge [Zn(BTA)(2)] fragments along [001]. Cations and anions are linked by N-H center dot center dot center dot N hydrogen-bond interactions along [010].”
“Since the introduction of propofol, several drugs and methods have been used to alleviate the pain on its injection. This study was designed to evaluate the effect of adding sevoflurane 3% during preoxygenation in alleviation of pain on propofol injection.\n\nIn this randomized single-blinded study, 100 patients were randomly allocated equally into five groups: sevoflurane-lidocaine-tourniquet (SLT), sevoflurane-lidocaine (SL), lidocaine-tourniquet

(LT), lidocaine (L), and sevoflurane GW4869 ic50 (S). Approximately 10 min before the induction of anesthesia, midazolam 1-2 mg was administered intravenously to all patients. All patients received fentanyl 1 A mu g/kg as pretreatment check details and a full induction dose of propofol. A blinded anesthesia nurse assessed pain and hand movements throughout the injection of propofol.\n\nIn the SLT group, all patients (100%) were pain free and had no hand movements. There was no significant difference in pain grade or in hand movements between the L and the S groups,

or between the SLT and the SL groups. However, significant differences were observed in pain grade between the SLT and the L groups as well as between the SLT and the S groups. In addition, a significant difference in hand movement was observed only between the SLT and the S groups.\n\nThe addition of 3% sevoflurane at the time of preoxygenation for 1 min along with routine use of lidocaine-tourniquet completely prevented pain upon Rabusertib inhibitor propofol injection, whereas sevoflurane by itself provided similar analgesia to premixed lidocaine with propofol.”
“Objectives. This article stresses the importance of exclusion of malignant tumors as a cause of temporomandibular joint disorder, which is usually caused by intra-articular or musculoligamental dysfunction without considering malignant tumors as a cause of such complaints.\n\nMethod and Results. Three patients were referred to us because of persistent and recurrent temporomandibular joint dysfunction. All patients were treated more than once through their general practitioner, ear nose and throat physician, or dental physician without significant improvement. After adequate clinical and radiological examination, malignant tumors were discovered as a cause of such complaints.\n\nConclusions. Patients with primary or secondary tumors could present with symptoms simulating temporomandibular joint disorder and will therefore be treated similarly.